AGER and chronic obstructive pulmonary disease: Although the preclinical study of RAGE against COPD reinforces the fact that RAGE may be a potential therapeutic target, future preclinical and clinical studies are necessary to evaluate the safety and efficacy of RAGE antagonists in COPD inflammation.